Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Translational Therapies for Mesothelioma
share announcement

Translational Therapies for Mesothelioma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (5 December 2022) | Viewed by 5717

Special Issue Editor

Prof. Dr. Luciano Mutti

E-Mail Website
Guest Editor
Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
Interests: translational vancer research; thoracic oncology; mesothelioma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis because of the poor response to all the treatments tested so far.

Most of the clinical trials run for this tumour have been based on drugs with some efficacy for other malignancies but without a specific background for MPM.

We reckon that this “random approach” is one of the most relevant reasons why the prognosis of these patients has been substantially unchanged from 2003 when the current front-line chemotherapy was approved.

Every step forward in therapy for human cancer has always been laid on the preclinical working ground, and thus we are firmly convinced the same workstream will generate more solid achievements for this neoplasm as well.

In the light of the most recent findings, tumour metabolism, immunometabolism and microenvironment will be particularly screened as new druggable targets

Therefore, we are asking some world-class groups known for working on innovative topics with the potential of being game-changers for MPM to provide us with their results and their understanding of the best direction to take in order to achieve better treatments for these patients.

Dr. Luciano Mutti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • malignant mesothelioma
  • translational therapies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 276 KiB  
Article
Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database
by Asad Ullah, Abdul Waheed, Jaffar Khan, Ankita Mishra, Bisma Tareen, Noor Nama, Nabin Raj Karki, Muhammad Saleem Panezai, Luis Velasquez Zarate, Joseph White, Frederick D. Cason, Nathaniel Matolo, Subhasis Misra and Nagla Abdel Karim
Cancers 2022, 14(4), 942; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14040942 - 14 Feb 2022
Cited by 12 | Viewed by 2740
Abstract
Background: Primary peritoneal mesothelioma (PPM) is a rare and aggressive tumor arising from the visceral and parietal peritoneum. The diagnosis and treatment of PPM are often delayed because of non-specific clinical presentation, and the prognosis is worse. The current study investigated the demographic, [...] Read more.
Background: Primary peritoneal mesothelioma (PPM) is a rare and aggressive tumor arising from the visceral and parietal peritoneum. The diagnosis and treatment of PPM are often delayed because of non-specific clinical presentation, and the prognosis is worse. The current study investigated the demographic, clinical, and pathological factors affecting patient prognosis and survival in PPM. Methods: Demographic and clinical data of 1998 patients with PPM were extracted from the Surveillance Epidemiology and End Results (SEER) database (1975–2016). The chi-square test, paired t-test, and multivariate analysis were used to analyze the data. Results: The majority of PPM patients were male (56.2%, p < 0.005) and Caucasian (90.4%, p < 0.005, with a mean age of diagnosis was 69 ± 13 years. The grading, histological, and tumor size information were classified as “Unknown” in most of the cases, but when available, poorly differentiated tumors (8.7%), malignant mesothelioma, not otherwise specified (63.4%) and tumors > 4 cm in size (8%), respectively, were most common, p < 0.005. Chemotherapy was administered to 50.6% of patients, followed by resection (29.2%) and radiation (1.5%), p < 0.001. The cohort of PPM had a five-year overall survival of 20.3% (±1.1), compared to 43.5% (±5.9), 25.9% (± 8.4), and 18.7% (±1.6) for those with surgery, radiation, or chemotherapy alone, respectively. Poor differentiation (OR = 4.2, CI = 3.3–4.9), tumor size > 4 cm (OR = 3.9, CI = 3.2–4.5), Caucasian race (OR = 2.9, CI = 2.6–4.4), and distant SEER stage (OR = 2.5, CI = 1.1–3.2) were all linked with increased mortality (p < 0.001). Conclusion: An extremely rare and aggressive peritoneal tumor, PPM may be difficult to identify at the time of diagnosis. Radiation therapy likely to have a limited function in the treatment of this condition, with surgery and chemotherapy being the primary choices. All PPM patients should be enrolled in a nationwide registry to improve our understanding of the pathogenesis and identify factors affecting survival. Full article
(This article belongs to the Special Issue Translational Therapies for Mesothelioma)

Review

Jump to: Research

25 pages, 1992 KiB  
Review
Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases
by Lara Perryman and Steven G. Gray
Cancers 2022, 14(4), 981; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14040981 - 15 Feb 2022
Cited by 3 | Viewed by 2359
Abstract
Immunotherapies (such as checkpoint inhibitors) and standard chemotherapies (such as cisplatin) have limitations in the successful treatment of malignant pleural mesothelioma (MPM). Fibrosis is the accumulation of collagen in the extracellular matrix (ECM) of tissues, making them denser than that of healthy tissues [...] Read more.
Immunotherapies (such as checkpoint inhibitors) and standard chemotherapies (such as cisplatin) have limitations in the successful treatment of malignant pleural mesothelioma (MPM). Fibrosis is the accumulation of collagen in the extracellular matrix (ECM) of tissues, making them denser than that of healthy tissues and thereby affecting drug delivery and immune cell infiltration. Moreover, fibrosis severely affects the patient’s breathing and quality of life. The production of collagen and its assembly is highly regulated by various enzymes such as lysyl oxidases. Many solid tumors aberrantly express the family of lysyl oxidases (LOX/LOXL). This review examines how LOX/LOXLs were found to be dysregulated in noncancerous and cancerous settings, discusses their roles in solid tumor fibrosis and pathogenesis and explores the role of fibrosis in the development and poor clinical outcomes of patients with MPM. We examine the current preclinical status of drugs targeting LOX/LOXLs and how the incorporation of such drugs may have therapeutic benefits in the treatment and management of patients with MPM. Full article
(This article belongs to the Special Issue Translational Therapies for Mesothelioma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop